Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex for anxiety in refractory pediatric epilepsy
NCT05324449Phase 4Completed
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger
- Start
- Apr 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cannabidiol in anxiety disorder, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger. Primary endpoint: Clinical Global Impression - Improvement at 16 weeks. Started Apr 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT05324449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324449.